Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 39 OC7.4 | DOI: 10.1530/endoabs.39.OC7.4

BSPED2015 ORAL COMMUNICATIONS Oral Communications 7 (6 abstracts)

The cost-effectiveness of the KIds in control of food structured education programme for adolescents with type 1 diabetes

Hasan Basirir 2 , Alan Brennan 1 , Richard Jacques 1 , Daniel Pollard 1 , Katherine Stevens 1 , Jennifer Freeman 5 , Jeremy Wales 4 & Katherine Price 3


1School of Health and Related Research, University of Sheffield, Sheffield, UK; 2Evidera, London, UK; 3Sheffield Children’s NHS Foundation Trust, Sheffield, UK; 4Lady Cilento Children’s Hospital, Brisbane, Australia; 5University of Leeds, Leeds, UK.


Objectives: Kids in control of food (KICK-OFF) is a 5-day structured education programme for 11–16 year olds with type 1 diabetes who use multiple daily insulin injections. This study evaluates whether KICk-OFF would be considered a cost effective use of NHS resources by decision makers in the UK.

Methods: A cost effectiveness analysis comparing KICk-OFF to usual care was conducted. Data from the KICk-OFF trial were extrapolated to simulate lifetime outcomes using the Sheffield type 1 diabetes policy model. Baseline patient characteristics and effectiveness on HbA1c, severe hypoglycaemia and diabetic ketoacidosis came from the trial data. In the model HbA1c is the key predictor of future events (retinopathy, neuropathy, nephropathy, myocardial infarction, stroke, revascularisation and angina). KICk-OFF implementation costs were calculated using data from participating trial centres. Analysis was conducted in the full cohort and a high baseline HbA1c (>9.5%; 80 mmol/mol) subgroup. Treatment effect durations of 2 years, 4 years and lifetime were tested. Uncertainty was examined using probabilistic sensitivity analysis.

Results: Using the full cohort and 4 year treatment effect duration, KICk-OFF provided more quality adjusted life years (+0.0394 QALYs) at a higher cost (£1135) per person than usual care. The incremental cost per QALY gained was £28 813 per QALY gained, just within the range of £20–30 000 which NICE would consider cost effective (42.6% chance of being below £20 000). In the full cohort the value changed considerably with the treatment effect duration. For the high HbA1c subgroup, KICk-OFF was dominant i.e. provided more QALYs (+0.2012) at a lower cost (−£4,423) per person (96.4% chance of being below £20 000). In this subgroup results were robust to different treatment effect durations.

Conclusions: For the whole study population, whether KICk-OFF is cost effective depends on the long-term treatment effect duration. For the high baseline HbA1c subgroup, KICk-OFF was found to be cost effective.

Volume 39

43rd Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.